Determination of risk factors associated with inflammation in hypertensive patients with type-2 diabetes mellitus in a Palestinian Diabetes Study

References

• Mackay J, Mensah G. 2004. Atlas of heart disease and stroke. Geneva: World Health Organization.
   Google Scholar
• Krause T, Lovibond K, Caulfield M, Guideline Development Group, et al. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.
   PubMed Web of Science ®Google Scholar
• Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–2260.
   PubMed Web of Science ®Google Scholar
• Ogah OS, Okpechi I, Chukwuonye II, et al. Blood pressure, prevalence of hypertension and hypertension related complications in Nigerian Africans: a review. World J Cardiol. 2012;4(12):327–340.
   PubMedGoogle Scholar
• Mitu F, Rezuş E, Banu C, et al. Inflammatory markers in hypertensive patients and influence of some associated metabolic risk factor. Rev Med Chir Soc Med Nat Iasi. 2014;118(3):631–636.
   PubMedGoogle Scholar
• Ellulu MS, Rahmat A, Abed Y, et al. Assessment of differences on inflammatory and metabolic indicators between pre- and post-menopause women among hypertensive and/or diabetic patients. Trends in Medical Research. 2015;10(2):44–50.
   Google Scholar
• Mühlenbruch K, Joost HG, Boeing H, et al. Risk prediction for type 2 diabetes in the German population with the updated German Diabetes Risk Score (GDRS). Ernährungsumschau. 2014;61:90–93.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
   Google Scholar
• American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Supplement 1):S8–S16.
   Google Scholar
• Ceriello PA. Oxidative stress and diabetes associated complications. Endocrine Practice. 2006;12:60–62.
   PubMedGoogle Scholar
• Bruno RM, Penno G, Daniele G, et al. Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction. Diabetologia. 2012;55(6):1847–1855.
   PubMed Web of Science ®Google Scholar
• Gordon L, Ragoobirsingh D, Morrison E, et al. Dyslipidaemia in hypertensive obese type 2 diabetic patients in Jamaica. AOMS. 2010;5(5):701–708.
   Google Scholar
• Maschirow L, Khalaf K, Al-Aubaidy HA, et al. Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes – biomarkers as a possible tool for early disease detection for rural screening. Clin Biochem. 2015;48(9):581–585.
   PubMed Web of Science ®Google Scholar
• Kalyani RR, Saudek CD, Brancati FL, et al. Association of diabetes, comorbidities, and A1C with functional disability in older adults results from the National Health and Nutrition Examination Survey (NHANES), 1999–2006. Diabetes Care. 2010;33(5):1055–1060.
   PubMed Web of Science ®Google Scholar
• Weng X, Liu Y, Ma J, et al. Use of body mass index to identify obesity-related metabolic disorders in the Chinese population. Eur J Clin Nutr. 2006;60(8):931–937.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Overweight and obesity. Fact sheet No. 311. Updated January 2015. http://www.who.int/mediacentre/factsheets/fs311/en/.
   Google Scholar
• Samouda H, Ruiz-Castell M, Karimi M, et al. Metabolically healthy and unhealthy weight statuses, health issues and related costs: findings from the 2013–2015 European Health Examination Survey in Luxembourg. Diabetes Metabol. 2019;45(2):140–151.
   PubMed Web of Science ®Google Scholar
• Weber MA, Schiffrin E, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16(1):14–26.
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee SJ, Park H, et al. Adiponectin is associated with impaired fasting glucose in the non-diabetic population. Epidemiol Health. 2011;33:e2011007.
   PubMedGoogle Scholar
• Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S57–S63.
   PubMed Web of Science ®Google Scholar
• Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S64–S73.
   PubMed Web of Science ®Google Scholar
• Mirza S, Hossain M, Mathews C, et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine. 2012; 57(1):136–131.
   PubMed Web of Science ®Google Scholar
• Emanuela F, Grazia M, Marco DR, et al. Inflammation as a link between obesity and metabolic syndrome: review article. J Nutr Metabol. 2012;2012:1–7.
   Google Scholar
• Ricci R, Bevilacqua F. The potential role of leptin and adiponectin in obesity: a comparative review. Vet J. 2012;191(3):292–298.
   PubMed Web of Science ®Google Scholar
• Herder C, Schneitler S, Rathmann W, et al. Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab. 2007;92(12):4569–4574.
   PubMed Web of Science ®Google Scholar
• Ellulu MS, Patimah I, Khaza'ai H, et al. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851–863.
   PubMed Web of Science ®Google Scholar
• Al-Hamodi Z, Al-Habori M, Al-Meeri A, et al. Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetol Metab Syndr. 2014;6(1):99.
   PubMedGoogle Scholar
• Cirillo P, Sautin Y, Kanellis J, et al. Systemic inflammation, metabolic syndrome and progressive renal disease. Nephrol Dial Transplant. 2009;24(5):1384–1387.
   PubMed Web of Science ®Google Scholar
• Woodard G, Mehta V, Mackey R, et al. C-reactive protein is associated with aortic stiffness in a cohort of African American and white women transitioning through menopause. Menopause. 2011;18(12):1291–1297.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim IT, Park HB, et al. High-sensitivity C-reactive protein can predict major adverse cardiovascular events in Korean patients with type 2 diabetes. J Korean Med Sci. 2011;26(10):1322–1327.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation. 2003;108(12):e81–e85.
   PubMedGoogle Scholar
• Bahceci M, Gokalp D, Bahceci S, et al. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high-sensitivity c-reactive protein levels. Is adipocyte size associated with inflammation in adults? J Endocrinol Invest. 2007;30(3):210–214.
   PubMed Web of Science ®Google Scholar
• Mosleh M, Aljeesh YI, Dalal K. Burden of chronic disease in the Palestinian healthcare sector using Disability-Adjusted Life Years (DALY), Palestine. Diversity Equal Health Care. 2016;13(3):261–268.
   Google Scholar
• Centers for Disease Control and Prevention. Behavioral risk factor surveillance system survey questionnaire. Atlanta, Georgia: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
   Google Scholar
• World Health Organization (WHO) Department of Non-communicable Diseases. Global physical activity questionnaire: analysis guide. Geneva: WHO; 2002.
   Google Scholar
• World Health Organization (WHO). Obesity: preventing and managing the global epidemic: report of a WHO consultation. WHO Technical Report Series 894. Geneva: WHO; 2000.
   Google Scholar
• National Institute for Health and Clinical Excellence. Obesity: the prevention, identifiation, assessment and management of overweight and obesity in adults and children. London: National Institute for Health and Clinical Excellence; 2006.
   Google Scholar
• Abdeen Z, Jildeh C, Dkeideek S, et al. Overweight and obesity among Palestinian adults: analyses of the anthropometric data from the First National Health and Nutrition Survey (1999–2000). J Obesity. 2012;2012:1–12.
   Google Scholar
• El Kishawi R, Soo KL, Abed YA, et al. Obesity and overweight: prevalence and associated socio demographic factors among mothers in three different areas in the Gaza Strip-Palestine: a cross-sectional study. BMC Obes. 2014;1(1):7.
   PubMedGoogle Scholar
• Ellulu MS, Abed Y. Effect of socio-demographic factors and obesity on blood pressure among adults based on health status in Gaza. J Public Health. 2017;25(3):289–297.
   Google Scholar
• Ellulu M, Rahmat A, Abed Y. Updates of overweight and obesity status and their consequences in Palestine. Pakistan J Nutr. 2014;13(2):116–121.
   Google Scholar
• Backes JM, Howard PA, Moriarty P. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother. 2004;38(1):110–118.
   PubMed Web of Science ®Google Scholar
• Devaraj S, Yun J, Adamson G, et al. C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res. 2009;84(3):479–484.
   PubMed Web of Science ®Google Scholar
• Han TS, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25(11):2016–2021.
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290(22):2945–2951.
   PubMed Web of Science ®Google Scholar
• Santos AC, Lopes C, Guimarães JT, et al. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes. 2005;29(12):1452–1456.
   Web of Science ®Google Scholar
• Kawamoto R, Tabara Y, Kohara K, et al. Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences in a Japanese community-dwelling population. Cardiovasc Diabetol. 2011;10(1):51.
   PubMedGoogle Scholar
• Ajani UA, Ford E, Mokdad A. Prevalence of high C-reactive protein in persons with serum lipid concentrations within recommended values. Clin Chem. 2004;50(9):1618–1622.
   PubMed Web of Science ®Google Scholar
• Stuveling EM, Hillege HL, Bakker S, et al. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int. 2003;63(2):654–661.
   PubMed Web of Science ®Google Scholar
• Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev. 2013;14(3):232–244.
   PubMed Web of Science ®Google Scholar
• Thompson A, Houck K, Adair L, et al. Risk factors for moderate inflammation in Chinese adults with and without central obesity (370.1). FASEB J. 2014;28(1 Suppl):370.
   Web of Science ®Google Scholar
• Connelly PW, Hanley AJ, Harris SB, et al. Relation of waist circumference and glycemic status to C-reactive protein in the Sandy Lake Oji-Cree. Int J Obes. 2003;27(3):347–354.
   Web of Science ®Google Scholar
• Lakoski SG, Cushman M, Criqui M, et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006;152(3):593–598.
   PubMed Web of Science ®Google Scholar
• Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878–888.
   PubMed Web of Science ®Google Scholar
• Chen SJ, Yen CH, Huang YC, et al. Relationships between inflammation, adiponectin, and oxidative stress in metabolic syndrome. PLOS One. 2012;7(9):e45693.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867.
   PubMed Web of Science ®Google Scholar
• Hansen D, Dendale P, Beelen M, et al. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to nonobese, type 2 diabetes patients. Eur J Appl Physiol. 2010;109(3):397–404.
   PubMed Web of Science ®Google Scholar
• Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am. 2008;37(3):753–768.
   PubMed Web of Science ®Google Scholar
• Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46(11):2347–2355.
   PubMed Web of Science ®Google Scholar
• Trayhurn P, Wood I. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(3):347–355.
   PubMed Web of Science ®Google Scholar
• Karastergiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol. 2010;318(1–2):69–78.
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu Q, Wang J, et al. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem Biophys Res Commun. 2009;379(2):476–479.
   PubMed Web of Science ®Google Scholar
• Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6(6):399–409.
   PubMed Web of Science ®Google Scholar
• Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. The implication of obesity on total antioxidant capacity in apparently healthy men and women: the ATTICA study. Nutr Metab Cardiovasc Dis. 2007;17(8):590–597.
   PubMed Web of Science ®Google Scholar
• Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, et al. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr. 2012;107(S2):S201–S213.
   PubMedGoogle Scholar
• Badawi A, Klip A, Haddad P, et al. Type 2 diabetes mellitus and inflammation: prospects for biomarkers of risk and nutritional intervention. DMSO. 2010;3:173–186.
   Google Scholar
• Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie. 2012;94(10):2137–2142.
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3 T3-L1 adipocytes. Biochem Biophys Res Commun. 2003;301(4):1045–1050.
   PubMed Web of Science ®Google Scholar
• Pradhan A, Manson J, Rifai N, et al. C-Reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale H, Villuendas G, Botella-Carretero J, et al. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia. 2003;46(5):625–633.
   PubMed Web of Science ®Google Scholar
• Visser M, Bouter L, McQuillan G, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131–2135.
   PubMed Web of Science ®Google Scholar
• Indulekha K, Surendar J, Anjana R, et al. Metabolic obesity, adipocytokines, and inflammatory markers in Asian Indians-CURES-124. Diabetes Technol Ther. 2015;17(2):134–141.
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Whincup PH, Rumley A, et al. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost. 2007;5(8):1637–1643.
   PubMed Web of Science ®Google Scholar
• Tsilchorozidou T, Mohamed-Ali V, Conway GS. Determinants of interleukin-6 and C-reactive protein vary in polycystic ovary syndrome, as do effects of short- and long-term metformin therapy. Horm Res. 2009;71(3):148–154.
   PubMedGoogle Scholar
• Ridker PM, Rifai N, Meir J, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767–1772.
   PubMed Web of Science ®Google Scholar
• Sedighi O, Abediankenari S. Relationship between plasma adiponectin level with inflammatory and metabolic markers in patients with chronic kidney disease. Nephrourol Month. 2013;6(1):e11743.
   PubMedGoogle Scholar
• Hung J, McQuillan BM, Thompson PL, et al. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes. 2008;32(5):772–779.
   Web of Science ®Google Scholar